Changeflow GovPing Pharma & Drug Safety Nanjing University of Chinese Medicine - US1260...
Routine Notice Added Final

Nanjing University of Chinese Medicine - US12600724B2 Indole Alkaloid Compound and Preparation Method

Favicon for changeflow.com USPTO Patent Grants - Organic Chemistry (C07D)
Published
Detected
Email

Summary

The USPTO granted Patent US12600724B2 to Nanjing University of Chinese Medicine for an indole alkaloid compound represented by formula (I), including its preparation method and pharmaceutical salts. The compound has demonstrated therapeutic effects in animal studies, including promoting axon growth in peripheral sensory neurons, improving nerve conduction velocity in diabetic rats, accelerating foot ulcer wound healing, reducing pulmonary fibrosis, and protecting lung tissues. The patent contains 13 claims covering the compound, formulations, and methods of treatment for diabetic complications.

What changed

The USPTO issued Patent US12600724B2 to Nanjing University of Chinese Medicine for an indole alkaloid compound with therapeutic applications in diabetic complications. The patent covers the compound, its preparation method, pharmaceutical salts, prodrugs, metabolites, and isomers. Experimental data in the patent demonstrates the compound's efficacy in promoting peripheral sensory neuron axon growth, improving nerve conduction velocity, and healing diabetic foot ulcers in rat models.

For pharmaceutical companies developing treatments for diabetic neuropathy or diabetic foot ulcers, this patent represents potential licensing opportunities or a competitive constraint requiring freedom-to-operate analysis. The patent's broad claim scope covering multiple forms of the compound and therapeutic uses may limit market entry for similar indole alkaloid-based therapies without licensing arrangements with the patent holder.

What to do next

  1. Monitor patent landscape for freedom-to-operate considerations
  2. Review patent claims for potential licensing opportunities
  3. Conduct prior art searches before developing similar compounds

Archived snapshot

Apr 15, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Grants

Indole alkaloid and preparation method and use thereof

Grant US12600724B2 Kind: B2 Apr 14, 2026

Assignee

NANJING UNIVERSITY OF CHINESE MEDICINE

Inventors

Xu Shen, Sheng Jiang, Kuojun Zhang, Jiaying Wang, He Tang, Yujie Huang, Tong Zhao, Minyi Qian

Abstract

A compound represented by formula (I) and a preparation method thereof, and a pharmaceutically acceptable salt thereof, a metabolic precursor thereof, a metabolite thereof, an isomer thereof or a prodrug thereof; experiments show that the indole alkaloid not only promotes axon growth of peripheral sensory neurons, improves the nerve conduction velocity and anesthesia symptom of diabetic rats, but also promotes healing of foot ulcer wounds of diabetic rats, thus having good therapeutic effects on diabetic complication peripheral neuropathy and diabetic feet; they also show that the indole alkaloid also obviously reduces a degree of pulmonary fibrosis induced by bleomycin in mice, and plays a role in protecting lung tissues.

CPC Classifications

C07D 471/22 A61K 31/4375 A61K 31/765 A61K 38/00 A61P 11/00 A61P 17/02 A61P 25/02 A61P 3/10 Y02P 20/55 C07K 5/06139 C07K 5/0821 C08G 65/33396 C07B 2200/07

Filing Date

2022-11-09

Application No.

18264435

Claims

13

View original document →

Get daily alerts for USPTO Patent Grants - Organic Chemistry (C07D)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
April 14th, 2026
Instrument
Notice
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
US12600724B2

Who this affects

Applies to
Drug manufacturers Pharmaceutical companies Healthcare providers
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Patent licensing Pharmaceutical research Drug development
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Healthcare Pharmaceuticals

Get alerts for this source

We'll email you when USPTO Patent Grants - Organic Chemistry (C07D) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!